 Participants will be randomized to either one of the investigational approaches Cohort II or to a control group receiving standard dose therapy Cohort I. There are two study visits in the first month; after the first month, study visits are scheduled monthly for five additional months. Study visits include laboratory tests of virologic and immunologic parameters, pharmacokinetic sampling, and adherence counseling and monitoring. 